72 CHAPTER 4 Table 1 | Summary table of preventive interventional trials in individuals at risk of developing rheumatoid arthritis (continued) Trial name Inclusion criteria Number of patients (treatment vs placebo) Intervention Time of follow-up Primary outcome Secondary outcome Results Reference STAPRA study - Arthralgia - ACPA LN or - ACPA and IgM-RF positivity 62 patients (31 treatment vs 31 placebo) 40 mg atorvastatin daily for 3 years - 1 month - 6 months - 5 years - Development of clinical arthritis (≥1 swollen joint out of SJC44) - Development of RA per ACR/EULAR 2010 criteria - Prematurely stopped – Treatment: 5-26 months follow-up; Placebo: 3-17 months follow-up - No significant difference in RA development (29% in treatment vs 19% in placebo group) [68,69] Stop RA - FDR - 2x elevated anti-CCP3 levels - Absence of clinical joint inflammation 114 patients 200-400 mg/ daily Hydroxychloroquine for 1 year - 52 weeks - 3 years - RA progression as per ACR/ EULAR 2010 criteria - Change in disease activity (joint pain, swelling, stiffness, and fatigue) at 1 and 3 years - Changes in self-reported Physical, Mental and Social Health Quality of Life Measures at 1 and 3 years - Waiting for results (primary completion date set for November 2023) [40]
RkJQdWJsaXNoZXIy MTk4NDMw